Global healthcare data technology company, Prospection, and leading Asia-Pacific biotech specialist CRO, Novotech Health Holdings, announce an strategic partnership to combine the power of real world evidence and clinical trials to get medicines to patients faster.  The partnership includes an investment by Novotech in Prospection.

Under the partnership, Prospection will become a technology partner of Novotech, providing its proprietary real world data analytics to support clinical trial feasibility assessment, execution and recruitment in the Asia-Pacific region.

“Real world evidence has reached a value inflection point becoming broadly accepted and increasingly utilised by regulatory authorities, as we’ve seen with its application to help manage COVID-19. The combination of our real world data analytics with Novotech’s clinical development expertise and footprint across the Asia-Pacific region brings together two nimble companies focused on generating evidence to support healthcare innovation and ultimately improve health outcomes for patients,” said CEO Eric Chung.

“By making an investment in Prospection and entering into this partnership, Novotech will add best-in-class data and analytics capabilities to our existing region leading biotech-focused suite of services for our clients,” said Novotech CEO Dr John Moller. 

“Driven by Prospection’s data analytics, our clients would benefit from more accurate patient identification, faster patient recruitment, compressed trial timelines and analytics capabilities to power real world clinical trials,” he added.

Prospection uses advanced analytics and AI algorithms to follow millions of patients over time to search for patterns in their health and the effectiveness of therapeutic journeys which can be harnessed in phase 4 studies. It can produce real world evidence in weeks that would have otherwise taken years to collect and analyse in a clinical trial.

Equally important, the partnership will help speed up trial design and feasibility as well as patient recruitment into trials. Patient recruitment can be one of the biggest hurdles in developing medicines, particularly in complex trials or when looking for patients within disease sub-segments or with rare diseases. 

Prospection’s analytics technology ingests de-identified patient data from varied sources, including healthcare providers and health records. This enables it to geolocate trial investigators or study sites with patients meeting the study criteria, thereby identifying locations for high recruitment potential. 

As part of the partnership, Novotech has made a minority equity investment in Prospection. This follows Prospection’s $45m Series B round in September 2021. 

 關於 Novotech Novotech-CRO.com

Novotech成立於 1997 年,立足亞太,面向全球,是專業的生物技術合同研究組織(CRO)。

Novotech因其在行業內的突出貢獻而備受讚譽,曾榮獲多項殊榮,其中包括 2023 年 CRO 領導力獎 (CRO Leadership Award 2023) 、2023 年亞太地區細胞與基因治療臨床試驗卓越獎 (Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023)和自 2006 年以來蟬聯亞太地區合同研究組織年度公司獎 (Asia-Pacific Contract Research Organization Company of the Year Award)。

Novotech是一家包含實驗室、Ⅰ期臨床中心、藥物開發諮詢服務和專業FDA法規服務的臨床CRO,擁有超5,000 項臨床專案經驗,包括Ⅰ期至Ⅳ期臨床試驗。Novotech專注於服務在亞太、美國與歐洲等地進行臨床試驗的生物技術客戶。Novotech目前在全球34個辦公地點共擁有3000多名員工。

如欲了解更多資訊或與專家團隊成員交談,請造訪 www.Novotech-CRO.com